Russia Cell And Gene Therapy Manufacturing Market Size & Outlook
Related Markets
Russia cell and gene therapy manufacturing market highlights
- The Russia cell and gene therapy manufacturing market generated a revenue of USD 150.6 million in 2022 and is expected to reach USD 906.6 million by 2030.
- The Russia market is expected to grow at a CAGR of 25.2% from 2023 to 2030.
- In terms of segment, cell therapy was the largest revenue generating therapy type in 2022.
- Gene Therapy is the most lucrative therapy type segment registering the fastest growth during the forecast period.
Cell and gene therapy manufacturing market data book summary
| Market revenue in 2022 | USD 150.6 million |
| Market revenue in 2030 | USD 906.6 million |
| Growth rate | 25.2% (CAGR from 2023 to 2030) |
| Largest segment | Cell therapy |
| Fastest growing segment | Gene Therapy |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Gene Therapy, Cell Therapy |
| Key market players worldwide | Lonza Group Ltd, Bluebird bio Inc, Catalent Inc, Roche, Samsung BioLogics, Boehringer Ingelheim, Hitachi Ltd, Takara Bio Inc, Miltenyi Biotec, Thermo Fisher Scientific Inc, Novartis AG ADR, Merck KGaA, Wuxi AppTec Co Ltd |
Other key industry trends
- In terms of revenue, Russia accounted for 2.1% of the global cell and gene therapy manufacturing market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, France cell and gene therapy manufacturing market is projected to lead the regional market in terms of revenue in 2030.
- France is the fastest growing regional market in Europe and is projected to reach USD 3,354.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell And Gene Therapy Manufacturing Market Scope
Cell And Gene Therapy Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Samsung BioLogics | View profile | 1001-5000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | https://www.samsungbiologics.com/ |
| Bluebird bio Inc | View profile | 323 | 455 Grand Union Boulevard, Somerville, MA, United States, 02145 | https://www.bluebirdbio.com |
| Miltenyi Biotec | View profile | 1001-5000 | Bergisch Gladbach, Nordrhein-Westfalen, Germany, Europe | http://www.miltenyibiotec.com |
| Roche | View profile | 10001+ | Basel, Basel-Stadt, Switzerland, Europe | http://www.roche.com |
| Catalent Inc | View profile | 17219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | https://www.catalent.com |
| Wuxi AppTec Co Ltd | View profile | 41116 | 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, China, People's Republic of, 200131 | https://www.wuxiapptec.com |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | https://www.boehringer-ingelheim.com/ |
| Takara Bio Inc | View profile | 1793 | Nojihigashi 7-4-38 Kusatu, Shiga, Otsu, Japan, 520-0058 | http://www.takara-bio.co.jp |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
| Hitachi Ltd | View profile | 322525 | 6-6, Marunouchi 1-chome, Chiyoda-ku, Tokyo, Japan, 100-8280 | http://www.hitachi.com |
| Merck KGaA | View profile | 62345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | https://www.emdgroup.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
Russia cell and gene therapy manufacturing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy manufacturing market will help companies and investors design strategic landscapes.
Cell therapy was the largest segment with a revenue share of 63.61% in 2022. Horizon Databook has segmented the Russia cell and gene therapy manufacturing market based on gene therapy, cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.
The Russian healthcare and pharmaceutical markets have huge potential for stem cell studies & clinical trials owing to large clinical trial participation, favorable currency exchange rates, and quick patient enrollment. Quick patient enrollment is important for early phase trials to facilitate faster project initiation.
Moreover, constant government support coupled with rapid advancements in the cell & gene therapy manufacturing field is contributing to regional growth. The federal law on biomedical cell products, which came into effect in 2017, was introduced in Russia permitting the use of living cells for therapy.
This law would further boost the development of biomedical research, and patients would receive effective treatment with the use of artificially grown cells. However, owing to the current invasion of Ukraine by Russia, several countries have imposed restrictions against Russia and most private companies have removed their services from the country.
Reasons to subscribe to Russia cell and gene therapy manufacturing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Russia cell and gene therapy manufacturing market databook
-
Our clientele includes a mix of cell and gene therapy manufacturing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Russia cell and gene therapy manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Russia cell and gene therapy manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Russia cell and gene therapy manufacturing market size, by cell therapy, 2018-2030 (US$M)
Russia Cell And Gene Therapy Manufacturing Market Outlook Share, 2022 & 2030 (US$M)
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
